pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,173 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints639BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps37globenewswire health28
therapy area
allOncology5001Rare Disease847Cardiology802Hematology768Immunology732Psychiatry & CNS582Pulmonology570
  • Experts wonder ‘Where is the CDC?’ as hantavirus outbreak unfolds
    The CDC is playing an unusually small, and quiet, role in responding to the hantavirus outbreak.
    STAT · 2mo ago↗ source
  • Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national news
    “We want, we need to keep medicine local. I think that's good for patients, it's good for communities,” Dr. Glaucomflecken says on the “First Opinion Podcast.”
    STAT · 2mo ago↗ source
  • Opinion: RFK Jr. allegedly ‘collected’ a dead raccoon’s penis. Was it bioethically justifiable?
    There are scientific reasons to study raccoon reproductive anatomy. But did RFK Jr.’s actions fit within a bioethical framework?
    STAT · 2mo ago↗ source
← prev
page 39 of 47
next →
fda recalls22
fda press21
fda medwatch18
Vaccines516
Endocrinology & Metabolism290
Ophthalmology255
Infectious Disease253
Nephrology239
  • Spain readies for evacuations as a hantavirus-hit cruise ship heads for the Canary Islands
    Spanish authorities on Friday were preparing to receive more than 140 passengers and crew members on board a hantavirus-stricken cruise ship headed for the Canary Islands.
    STAT · 2mo ago↗ source
  • STAT+: Roche to buy PathAI for $750 million
    Roche has signed a deal to acquire PathAI to speed up its use of artificial intelligence to help pathologists diagnose diseases.
    STAT · 2mo ago↗ source
  • Trump reportedly plans to fire FDA Commissioner Makary
    Makary's ouster would create another high-profile vacancy atop RFK Jr.'s health department.
    STAT · 2mo ago↗ source
  • STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
    Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.
    STAT · 2mo ago↗ source
  • Opinion: I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbook
    The cruise ship hantavirus outbreak is serious but limited. Online, it's another story.
    STAT · 2mo ago↗ source
  • Lilly to invest extra $4.5B across Indiana manufacturing
    The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.
    BioPharma Dive · 2mo ago↗ source
  • Former FDA leaders, pharma speak out on mifepristone
    “The fundamental question is: Who gets to regulate mifepristone?”
    STAT · 2mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 2mo ago↗ source
  • The biotechs wear Prada
    Was Naomi Osaka's Met Gala outfit inspired by Gilead's logo? Janelle Monáe's by Insilico's? Probably not — and yet.
    STAT · 2mo ago↗ source
  • FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
    Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: The biotech news you need to read today
    A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout
    STAT · 2mo ago↗ source
  • Lilly, Gilead lead pharma’s M&A boom
    Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more
    An FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on research
    STAT · 2mo ago↗ source
  • The aging scientific workforce collides with rising fabricating citations in medical journals
    The latest in the hantavirus cruise ship saga, why these former officials left the FDA, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • Opinion: We need more men in nursing
    Men make up just 12% of nurses nationally. That needs to change.
    STAT · 2mo ago↗ source
  • Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting
    “The pediatric and orphan pipeline is already the smallest, slowest, and least capitalized segment of the device industry,” writes Kolaleh Eskandanian.
    STAT · 2mo ago↗ source
  • Why we left the FDA: Six former officials share their stories
    In this week's STATus Report, hear from six former FDA officials on why they left the agency.
    STAT · 2mo ago↗ source
  • Odyssey, on second try, snags $279M in an IPO
    After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…
    BioPharma Dive · 2mo ago↗ source
  • Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers
    “Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study found
    STAT · 2mo ago↗ source
  • Sarepta tumbles as its gene therapy sales decline further
    Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.
    BioPharma Dive · 2mo ago↗ source
  • Key takeaways from WHO briefing on hantavirus cruise ship outbreak
    Here are key takeaways from a WHO briefing on the hantavirus outbreak aboard a cruise ship.
    STAT · 2mo ago↗ source
  • Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
    This week on "The Readout LOUD" podcast: Seaport Therapeutics’ successful IPO, obesity pill battles, and the FDA commissioner's White House troubles.
    STAT · 2mo ago↗ source